» Articles » PMID: 35264513

Myocardial T-Lymphocytes As a Prognostic Risk-Stratifying Marker of Dilated Cardiomyopathy - Results of the Multicenter Registry to Investigate Inflammatory Cell Infiltration in Dilated Cardiomyopathy in Tissues of Endomyocardial Biopsy (INDICATE...

Abstract

Background: Dilated cardiomyopathy (DCM) associated with inflammation is diagnosed by endomyocardial biopsy; patients with this have a poorer prognosis than patients without inflammation. To date, standard diagnostic criteria have not been established.

Methods and results: This study analyzed clinical records and endomyocardial biopsy samples of 261 patients with DCM (201 males, median left ventricular ejection fraction; 28%) from 8 institutions in a multicenter retrospective study. Based on the European Society of Cardiology criteria and CD3 (T-lymphocytes) and CD68 (macrophages) immunohistochemistry, 48% of patients were categorized as having inflammatory DCM. For risk-stratification, we divided patients into 3 groups using Akaike Information Criterion/log-rank tests, which can determine multiple cut-off points: CD3-Low, <13/mm(n=178, 68%); CD3-Moderate, 13-24/mm(n=58, 22%); and CD3-High, ≥24/mm(n=25, 10%). The survival curves for cardiac death or left ventricular assist device implantation differed significantly among the 3 groups (10-year survival rates: CD3-Low: 83.4%; CD3-Moderate: 68.4%; CD3-High: 21.1%; Log-rank P<0.001). Multivariate Cox analysis revealed CD3count as a potent independent predictive factor for survival (fully adjusted hazard ratio: CD3-High: 5.70, P<0.001; CD3-Moderate: 2.64, P<0.01). CD3-High was also associated with poor left ventricular functional and morphological recovery at short-term follow up.

Conclusions: Myocardial CD3T-lymphocyte infiltration has a significant prognostic impact in DCM and a 3-tiered risk-stratification model could be helpful to refine patient categorization.

Citing Articles

Diverse Concepts in Definitions of Dilated Cardiomyopathy: Theory and Practice.

Myers M, Breznen B, Zhong Y, Maruyama S, Bueno C, Bastien A Cardiol Res. 2024; 15(5):319-329.

PMID: 39420975 PMC: 11483116. DOI: 10.14740/cr1679.


Novel Immunohistochemical and Morphological Approaches in a Retrospective Study of Post-Mortem Myocarditis.

Neagu O, Chirica V, Luca L, Bosa M, Tita A, Ceausu M Medicina (Kaunas). 2024; 60(8).

PMID: 39202593 PMC: 11356551. DOI: 10.3390/medicina60081312.


Cardiovascular Magnetic Resonance Radiomics to Identify Components of the Extracellular Matrix in Dilated Cardiomyopathy.

Nakamori S, Amyar A, Fahmy A, Ngo L, Ishida M, Nakamura S Circulation. 2024; 150(1):7-18.

PMID: 38808522 PMC: 11216881. DOI: 10.1161/CIRCULATIONAHA.123.067107.


Can right ventricular endomyocardial biopsy predict left ventricular fibrosis beforehand in dilated cardiomyopathy?.

Amemiya K, Matsuyama T, Ishibashi-Ueda H, Morita Y, Matsumoto M, Ohta-Ogo K ESC Heart Fail. 2024; 11(2):1001-1008.

PMID: 38234242 PMC: 10966220. DOI: 10.1002/ehf2.14642.


MicroRNAs as novel biomarkers and potential therapeutic options for inflammatory cardiomyopathy.

Aleshcheva G, Baumeier C, Harms D, Bock C, Escher F, Schultheiss H ESC Heart Fail. 2023; 10(6):3410-3418.

PMID: 37679968 PMC: 10682862. DOI: 10.1002/ehf2.14523.